FY2027 EPS Estimates for Biogen Inc. Increased by Analyst (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIBFree Report) – Equities research analysts at Hsbc Global Res increased their FY2027 earnings estimates for Biogen in a research report issued to clients and investors on Monday, July 8th. Hsbc Global Res analyst M. Herholdt now expects that the biotechnology company will earn $22.39 per share for the year, up from their prior forecast of $22.33. The consensus estimate for Biogen’s current full-year earnings is $15.63 per share. Hsbc Global Res also issued estimates for Biogen’s FY2028 earnings at $24.30 EPS.

Several other analysts have also recently commented on the stock. Bank of America decreased their price target on shares of Biogen from $280.00 to $260.00 and set a “neutral” rating on the stock in a research note on Friday, April 12th. Oppenheimer restated an “outperform” rating and set a $270.00 price objective on shares of Biogen in a report on Monday, April 29th. HSBC lifted their price target on shares of Biogen from $339.00 to $342.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $294.00 price target on shares of Biogen in a research note on Friday, June 28th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Biogen from $270.00 to $240.00 and set a “neutral” rating for the company in a research report on Thursday, April 11th. Ten analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Biogen has an average rating of “Moderate Buy” and an average target price of $286.50.

Check Out Our Latest Research Report on BIIB

Biogen Price Performance

BIIB opened at $232.75 on Thursday. Biogen has a one year low of $189.44 and a one year high of $281.68. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.10 and a quick ratio of 1.32. The company’s 50 day simple moving average is $225.78 and its 200-day simple moving average is $227.18. The stock has a market capitalization of $33.89 billion, a P/E ratio of 29.06, a price-to-earnings-growth ratio of 2.30 and a beta of -0.04.

Biogen (NASDAQ:BIIBGet Free Report) last posted its quarterly earnings data on Wednesday, April 24th. The biotechnology company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $3.45 by $0.22. The company had revenue of $2.29 billion during the quarter, compared to analyst estimates of $2.31 billion. Biogen had a net margin of 12.07% and a return on equity of 14.83%. The company’s revenue was down 7.0% on a year-over-year basis. During the same quarter last year, the business posted $3.40 earnings per share.

Hedge Funds Weigh In On Biogen

Several hedge funds and other institutional investors have recently made changes to their positions in BIIB. Leo Wealth LLC acquired a new position in Biogen during the 4th quarter worth approximately $2,265,000. ICICI Prudential Asset Management Co Ltd boosted its stake in Biogen by 15.0% during the fourth quarter. ICICI Prudential Asset Management Co Ltd now owns 35,989 shares of the biotechnology company’s stock worth $9,313,000 after acquiring an additional 4,693 shares in the last quarter. Dynamic Advisor Solutions LLC boosted its stake in Biogen by 6.2% during the fourth quarter. Dynamic Advisor Solutions LLC now owns 4,850 shares of the biotechnology company’s stock worth $1,251,000 after acquiring an additional 285 shares in the last quarter. Public Sector Pension Investment Board raised its holdings in Biogen by 12.2% during the third quarter. Public Sector Pension Investment Board now owns 15,550 shares of the biotechnology company’s stock worth $3,997,000 after buying an additional 1,690 shares during the last quarter. Finally, Everence Capital Management Inc. raised its holdings in Biogen by 26.6% during the fourth quarter. Everence Capital Management Inc. now owns 5,000 shares of the biotechnology company’s stock worth $1,294,000 after buying an additional 1,050 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Company Profile

(Get Free Report)

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

Featured Articles

Earnings History and Estimates for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.